FDA panel rejects xyrem as treatment for fibromyalgia
An FDA advisory panel today rejected sodium oxybate, the application of Jazz Pharmaceuticals, as a treatment for fibromyalgia.
An FDA advisory committee will meet today to review whether the antidepressant Cymbalta should be used as a treatment for chronic pain, despite risks that include liver damage and skin disease.